Ironwood Pharmaceuticals Inc (IRWD) is the 134th largest of 300 Biotechnology companies by market capitalisation, at 673.24 Mn, behind Aura Biosciences, Inc. at 686.81 Mn. It trades on a P/E of 3.05, 83% below the peer median of 18.42. The table below compares all 300 on 8 financial metrics.
| # | Ticker | Company | match | industry_code | industry_group | industry_group_code | Market Capitalization | P/E | P/S | Enterprise Value |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AMGN | Amgen Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 211.51 Bn | 24.19 | 5.55 | 197.52 Bn |
| 2 | GILD | Gilead Sciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 181.48 Bn | -62.69 | 5.96 | 178.30 Bn |
| 3 | VRTX | Vertex Pharmaceuticals Inc / Ma | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 132.45 Bn | 30.07 | 10.52 | 124.60 Bn |
| 4 | REGN | Regeneron Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 82.87 Bn | 19.14 | 5.33 | 74.88 Bn |
| 5 | ARGX | Argenx Se | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 61.59 Bn | 35.91 | 11.79 | 56.41 Bn |
| 6 | MRNA | Moderna, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 54.72 Bn | -17.37 | 24.56 | 49.59 Bn |
| 7 | ALNY | Alnylam Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 34.13 Bn | 44.05 | 7.10 | 30.82 Bn |
| 8 | BIIB | Biogen Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 31.29 Bn | 37.50 | 3.12 | 30.01 Bn |
| 9 | ROIV | Roivant Sciences Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 30.31 Bn | -20.42 | 2,774.76 | 30.31 Bn |
| 10 | INSM | INSMED Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 28.19 Bn | -32.21 | 24.78 | 27.03 Bn |
| 11 | BNTX | BioNTech SE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 23.56 Bn | -13.83 | 7.62 | 9.91 Bn |
| 12 | ASND | Ascendis Pharma A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 15.97 Bn | 18.42 | 11.27 | 15.03 Bn |
| 13 | MDGL | Madrigal Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 15.80 Bn | -49.53 | 12.31 | 14.96 Bn |
| 14 | BBIO | BridgeBio Pharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 14.63 Bn | -21.14 | 20.51 | 13.91 Bn |
| 15 | SMMT | Summit Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 13.59 Bn | — | — | 12.90 Bn |
| 16 | HALO | Halozyme Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.62 Bn | 30.51 | 7.59 | 12.39 Bn |
| 17 | BMRN | Biomarin Pharmaceutical Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.58 Bn | 172.37 | 3.69 | 11.70 Bn |
| 18 | ARWR | Arrowhead Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.05 Bn | -44.28 | 18.00 | 10.45 Bn |
| 19 | AAVXF | Abivax S.A. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.92 Bn | -25.97 | — | 10.92 Bn |
| 20 | APGE | Apogee Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.18 Bn | -34.62 | — | 9.20 Bn |
| 21 | PRAX | Praxis Precision Medicines, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.15 Bn | -26.60 | — | 9.39 Bn |
| 22 | PTGX | Protagonist Therapeutics, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.56 Bn | 86.59 | 33.91 | 9.56 Bn |
| 23 | IONS | Ionis Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.34 Bn | -43.99 | 10.68 | 7.28 Bn |
| 24 | PCVX | Vaxcyte, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.62 Bn | -8.15 | — | 8.62 Bn |
| 25 | IBRX | ImmunityBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.46 Bn | -8.52 | 51.02 | 8.10 Bn |
| 26 | IMVT | Immunovant, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.98 Bn | -14.83 | — | 7.98 Bn |
| 27 | TGTX | Tg Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.70 Bn | 17.43 | 9.63 | 7.02 Bn |
| 28 | GIFLF | Grifols SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.54 Bn | 29.70 | 0.46 | 9.09 Bn |
| 29 | SYRE | Spyre Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.54 Bn | -42.12 | — | 7.54 Bn |
| 30 | SRRK | Scholar Rock Holding Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.17 Bn | -17.76 | — | 7.17 Bn |
| 31 | RYTM | Rhythm Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.90 Bn | -32.84 | 28.78 | 6.57 Bn |
| 32 | CGON | CG Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.40 Bn | -28.54 | 1,027.23 | 6.40 Bn |
| 33 | MIRM | Mirum Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.36 Bn | -7.40 | 10.29 | 5.92 Bn |
| 34 | BLRX | BioLineRx Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.34 Bn | -707.43 | 4,551.55 | 6.34 Bn |
| 35 | KNSA | Kiniksa Pharmaceuticals International, plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.18 Bn | 76.63 | 7.35 | 5.65 Bn |
| 36 | COGT | Cogent Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.95 Bn | -16.09 | — | 5.95 Bn |
| 37 | DBVT | DBV Technologies S.A. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.88 Bn | -33.43 | 1,172.16 | 5.71 Bn |
| 38 | XENE | Xenon Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.85 Bn | -16.14 | — | 5.85 Bn |
| 39 | ORKA | Oruka Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.84 Bn | — | — | 4.11 Bn |
| 40 | LGND | Ligand Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.83 Bn | 29.56 | 20.06 | 4.47 Bn |
| 41 | PTCT | Ptc Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.62 Bn | 14.70 | 5.57 | 3.39 Bn |
| 42 | ERAS | Erasca, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.00 Bn | -17.40 | — | 5.00 Bn |
| 43 | CELC | Celcuity Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.98 Bn | -22.73 | — | 4.98 Bn |
| 44 | DNLI | Denali Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.09 Bn | -7.99 | 1,133.56 | 4.09 Bn |
| 45 | DNTH | Dianthus Therapeutics, Inc. /DE/ | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.05 Bn | — | — | 3.64 Bn |
| 46 | TLPPF | Telix Pharmaceuticals Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.89 Bn | -521.64 | 4.64 | 3.59 Bn |
| 47 | RLAY | Relay Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.86 Bn | -13.50 | 372.87 | 3.86 Bn |
| 48 | VKTX | Viking Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.83 Bn | -7.17 | — | 3.83 Bn |
| 49 | AMLX | Amylyx Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.69 Bn | -30.40 | — | 3.69 Bn |
| 50 | RCUS | Arcus Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.59 Bn | -7.79 | 30.64 | 2.88 Bn |
| 51 | TNGX | Tango Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.56 Bn | -34.83 | 66.23 | 2.55 Bn |
| 52 | IDYA | IDEAYA Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.56 Bn | -16.16 | 15.20 | 2.73 Bn |
| 53 | ABCL | AbCellera Biologics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.41 Bn | -20.72 | 51.55 | 3.41 Bn |
| 54 | DYN | Dyne Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.23 Bn | -6.26 | — | 3.23 Bn |
| 55 | ARQT | Arcutis Biotherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.14 Bn | 110.09 | 6.76 | 2.90 Bn |
| 56 | CLDX | Celldex Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.03 Bn | -9.85 | 19,169.33 | 3.03 Bn |
| 57 | IMNM | Immunome Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.99 Bn | -11.05 | 593.06 | 2.47 Bn |
| 58 | IRON | Disc Medicine, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.96 Bn | -14.68 | — | 2.96 Bn |
| 59 | MBX | MBX Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.94 Bn | -28.20 | — | 2.94 Bn |
| 60 | NRIX | Nurix Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.92 Bn | -8.55 | 79.42 | 2.48 Bn |
| 61 | ZLAB | Zai Lab Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.83 Bn | -15.04 | 6.30 | 2.12 Bn |
| 62 | SLS | SELLAS Life Sciences Group, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.64 Bn | -81.42 | — | 2.64 Bn |
| 63 | OCUL | Ocular Therapeutix, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.55 Bn | -8.43 | 49.05 | 2.55 Bn |
| 64 | VERA | Vera Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.47 Bn | -6.18 | — | 2.47 Bn |
| 65 | VRDN | Viridian Therapeutics, Inc.\DE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.43 Bn | -6.07 | 34.11 | 2.43 Bn |
| 66 | NKTR | Nektar Therapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.43 Bn | -20.41 | 44.44 | 1.74 Bn |
| 67 | BCRX | Biocryst Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.31 Bn | -6.01 | 4.32 | 1.96 Bn |
| 68 | XTLB | Xtl Biopharmaceuticals Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.29 Bn | -2,975.41 | — | 2.29 Bn |
| 69 | BHVN | Biohaven Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.29 Bn | -3.89 | — | 2.02 Bn |
| 70 | URGN | UroGen Pharma Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.28 Bn | -36.64 | 12.09 | 2.17 Bn |
| 71 | PHVS | Pharvaris N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.26 Bn | -11.37 | — | 1.89 Bn |
| 72 | GMAB | Genmab A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.16 Bn | 0.17 | 0.34 | 0.65 Bn |
| 73 | KOD | Kodiak Sciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.14 Bn | -8.86 | — | 2.14 Bn |
| 74 | CMPS | COMPASS Pathways plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.14 Bn | -5.42 | — | 2.14 Bn |
| 75 | ADMA | Adma Biologics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.14 Bn | 12.85 | 4.17 | 2.00 Bn |
| 76 | RAPP | Rapport Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.10 Bn | -15.28 | 104.76 | 2.10 Bn |
| 77 | AGIO | Agios Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.07 Bn | -5.04 | 21.09 | 2.07 Bn |
| 78 | ZBIO | Zenas BioPharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.05 Bn | -4.92 | 2,046.73 | 2.05 Bn |
| 79 | ZYME | Zymeworks Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.01 Bn | -13.37 | 54.02 | 1.73 Bn |
| 80 | STOK | Stoke Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.98 Bn | -9.52 | 71.67 | 1.68 Bn |
| 81 | XNCR | Xencor Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.92 Bn | -11.74 | 18.27 | 1.54 Bn |
| 82 | INBX | Inhibrx Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.85 Bn | -13.87 | 1,422.93 | 1.85 Bn |
| 83 | VIR | Vir Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.82 Bn | -7.22 | 5.99 | 1.82 Bn |
| 84 | IMCR | Immunocore Holdings plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.77 Bn | -98.05 | 4.12 | 0.89 Bn |
| 85 | SNDX | Syndax Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.77 Bn | -9.75 | 7.01 | 1.22 Bn |
| 86 | SEPN | Septerna, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.73 Bn | -123.96 | 17.50 | 1.73 Bn |
| 87 | GLPGF | Lakefront Biotherapeutics NV | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.73 Bn | 0.00 | 1.50 | 1.73 Bn |
| 88 | RXRX | Recursion Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.73 Bn | -3.33 | 31.50 | 1.18 Bn |
| 89 | GHRS | GH Research PLC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.68 Bn | -26.98 | — | 1.32 Bn |
| 90 | SCNI | Scinai Immunotherapeutics Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.63 Bn | -194.01 | 943.71 | 1.62 Bn |
| 91 | DMRA | Damora Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.62 Bn | -6.18 | — | 1.08 Bn |
| 92 | NVAX | Novavax Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.62 Bn | -6.55 | 3.92 | 0.90 Bn |
| 93 | ANAB | Anaptysbio, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.61 Bn | -67.34 | 8.08 | 1.32 Bn |
| 94 | BCAX | Bicara Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.60 Bn | -8.62 | — | 1.60 Bn |
| 95 | ATAI | AtaiBeckley Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.59 Bn | -10.36 | 525.18 | 1.59 Bn |
| 96 | FBRX | Forte Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.58 Bn | -20.71 | — | 1.23 Bn |
| 97 | AAPG | Ascentage Pharma Group International | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.54 Bn | -9.11 | 20.12 | 1.26 Bn |
| 98 | RARE | Ultragenyx Pharmaceutical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.50 Bn | -3.25 | 2.09 | 1.21 Bn |
| 99 | ANRO | Alto Neuroscience, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.48 Bn | -17.61 | — | 1.48 Bn |
| 100 | GLUE | Monte Rosa Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.46 Bn | -9.51 | 50.97 | 0.83 Bn |
| 101 | MAZE | Maze Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.45 Bn | -13.67 | 72.48 | 1.45 Bn |
| 102 | AVBP | ArriVent BioPharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.42 Bn | -8.67 | — | 1.42 Bn |
| 103 | REPL | Replimune Group, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.42 Bn | -4.78 | — | 1.42 Bn |
| 104 | TYRA | Tyra Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.42 Bn | -9.53 | — | 1.42 Bn |
| 105 | OMER | Omeros Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.39 Bn | 81.23 | 36.08 | 1.39 Bn |
| 106 | ORIC | Oric Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.38 Bn | -8.80 | — | 1.38 Bn |
| 107 | ABSI | Absci Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.38 Bn | -11.43 | 886.71 | 1.18 Bn |
| 108 | SVRA | Savara Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.37 Bn | -9.80 | — | 1.37 Bn |
| 109 | CGEM | Cullinan Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.33 Bn | -6.49 | — | 1.33 Bn |
| 110 | VOR | Vor Biopharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.29 Bn | -1.40 | — | 1.29 Bn |
| 111 | ALMS | Alumis Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.26 Bn | -5.20 | 151.28 | 0.76 Bn |
| 112 | JANX | Janux Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.23 Bn | -11.97 | 51.19 | 1.23 Bn |
| 113 | MNKD | Mannkind Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.22 Bn | -28.07 | 3.11 | 1.11 Bn |
| 114 | CRVS | Corvus Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.22 Bn | -25.57 | — | 1.01 Bn |
| 115 | JBIO | Jade Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.18 Bn | -7.67 | — | 1.18 Bn |
| 116 | CLYM | Climb Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.16 Bn | -20.19 | — | 1.16 Bn |
| 117 | MLTX | MoonLake Immunotherapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.03 Bn | -3.90 | — | 0.50 Bn |
| 118 | ABUS | Arbutus Biopharma Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.01 Bn | 6.65 | 5.57 | 0.92 Bn |
| 119 | WVE | Wave Life Sciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.98 Bn | -4.83 | 14.95 | 0.61 Bn |
| 120 | MNPR | Monopar Therapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.97 Bn | -70.29 | — | 0.92 Bn |
| 121 | OKYO | OKYO Pharma Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.97 Bn | -118.02 | — | 0.97 Bn |
| 122 | GERN | Geron Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.96 Bn | -14.29 | 3.94 | 0.66 Bn |
| 123 | ARDX | Ardelyx, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.92 Bn | -16.59 | 2.05 | 0.64 Bn |
| 124 | ANNX | Annexon, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.91 Bn | -4.43 | — | 0.91 Bn |
| 125 | TBPH | Theravance Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.88 Bn | 20.84 | 8.45 | 0.49 Bn |
| 126 | RIGL | Rigel Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.87 Bn | 2.72 | 3.16 | 0.78 Bn |
| 127 | STTK | Shattuck Labs, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.82 Bn | -15.17 | 818.91 | 0.82 Bn |
| 128 | AVTX | Avalo Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.81 Bn | -8.11 | — | 0.81 Bn |
| 129 | ACRS | Aclaris Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.81 Bn | -10.13 | 98.12 | 0.81 Bn |
| 130 | PHAR | Pharming Group N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.79 Bn | -128.18 | 2.39 | 0.64 Bn |
| 131 | CTMX | CytomX Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.77 Bn | -10.16 | 42.11 | 0.44 Bn |
| 132 | ZURA | Zura Bio Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.72 Bn | -6.22 | — | 0.72 Bn |
| 133 | AURA | Aura Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.69 Bn | -6.28 | — | 0.62 Bn |
| 134 | IRWD | Ironwood Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.67 Bn | 3.05 | 1.73 | 0.59 Bn |
| 135 | SLN | Silence Therapeutics plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.64 Bn | -16.54 | 1,045.35 | 0.57 Bn |
| 136 | ASMB | Assembly Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.63 Bn | 504.99 | 8.39 | 0.31 Bn |
| 137 | CBIO | Crescent Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.62 Bn | -3.80 | 595.95 | 0.45 Bn |
| 138 | ALT | Altimmune, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.61 Bn | -8.32 | — | 0.61 Bn |
| 139 | OCS | Oculis Holding AG | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.61 Bn | -346,460.81 | — | 0.61 Bn |
| 140 | BBOT | BridgeBio Oncology Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.60 Bn | -3.02 | — | 0.38 Bn |
| 141 | CTNM | Contineum Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.58 Bn | -9.62 | — | 0.58 Bn |
| 142 | TECX | Tectonic Therapeutic, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.58 Bn | -6.72 | — | 0.58 Bn |
| 143 | ARVN | Arvinas, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.57 Bn | 61.60 | 1.81 | 0.01 Bn |
| 144 | SGMT | Sagimet Biosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.57 Bn | -11.80 | — | 0.57 Bn |
| 145 | VALN | Valneva SE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.56 Bn | -9.64 | 3.37 | 0.42 Bn |
| 146 | IMUX | Immunic, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.53 Bn | -4.58 | — | 0.53 Bn |
| 147 | OABI | OmniAb, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.52 Bn | -11.71 | 13.48 | 0.47 Bn |
| 148 | PRLD | Prelude Therapeutics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.51 Bn | -7.60 | 22.84 | 0.23 Bn |
| 149 | PRTA | Prothena Corp Public Ltd Co | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.48 Bn | -11.00 | 8.85 | 0.19 Bn |
| 150 | KMDA | Kamada Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | 15.21 | 2.47 | 0.40 Bn |
| 151 | NEUP | Neuphoria Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | -19.85 | — | 0.45 Bn |
| 152 | ANL | Adlai Nortye Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | -10.27 | 78.36 | 0.24 Bn |
| 153 | RLMD | Relmada Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | -7.66 | — | 0.47 Bn |
| 154 | PBYI | Puma Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.46 Bn | 15.44 | 2.00 | 0.37 Bn |
| 155 | DRUG | Bright Minds Biosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | -15.52 | — | 0.45 Bn |
| 156 | CCCC | C4 Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | -4.46 | 12.91 | 0.20 Bn |
| 157 | AVIR | Atea Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.43 Bn | -3.11 | — | 0.43 Bn |
| 158 | RZLT | Rezolute, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.42 Bn | -5.20 | — | 0.42 Bn |
| 159 | CMPX | Compass Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.42 Bn | -5.15 | — | 0.42 Bn |
| 160 | ARCT | Arcturus Therapeutics Holdings Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.42 Bn | -4.39 | 14.24 | 0.23 Bn |
| 161 | BIOA | BioAge Labs, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.41 Bn | -4.32 | 39.21 | 0.41 Bn |
| 162 | LRMR | Larimar Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.40 Bn | -2.29 | — | 0.25 Bn |
| 163 | EVMN | Evommune, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.40 Bn | -4.19 | 39.64 | 0.20 Bn |
| 164 | EYPT | EyePoint, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.39 Bn | -1.27 | 140.72 | 0.21 Bn |
| 165 | ENTA | Enanta Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.39 Bn | -6.10 | 5.90 | 0.20 Bn |
| 166 | HMDCF | HUTCHMED (China) Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | — | — | 0.39 Bn |
| 167 | CATX | Perspective Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.36 Bn | -3.02 | — | 0.36 Bn |
| 168 | WHWK | Whitehawk Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.35 Bn | -4.37 | — | 0.35 Bn |
| 169 | FHTX | Foghorn Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | -5.14 | 9.19 | 0.27 Bn |
| 170 | EPRX | Eupraxia Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.33 Bn | -6.50 | — | 0.33 Bn |
| 171 | ELDN | Eledon Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | -3.89 | — | 0.32 Bn |
| 172 | UPB | Upstream Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | -1.98 | 100.39 | 0.32 Bn |
| 173 | STRO | Sutro Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.31 Bn | -2.69 | 3.40 | 0.14 Bn |
| 174 | TRDA | Entrada Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | -1.80 | 63.75 | 0.30 Bn |
| 175 | AGEN | Agenus Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | 3.16 | 2.19 | 0.29 Bn |
| 176 | SABS | SAB Biotherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | -4.13 | — | 0.28 Bn |
| 177 | ACIU | AC Immune SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | -5.20 | 12.71 | 0.28 Bn |
| 178 | BCYC | Bicycle Therapeutics Plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | -1.48 | 4.60 | 0.28 Bn |
| 179 | GALT | Galectin Therapeutics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | -9.86 | — | 0.28 Bn |
| 180 | EQ | Equillium, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | -15.20 | — | 0.27 Bn |
| 181 | FIXX | Q32 Bio Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | 67.73 | — | 0.16 Bn |
| 182 | ALEC | Alector, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -2.99 | 18.93 | 0.09 Bn |
| 183 | ALXO | Alx Oncology Holdings Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -3.17 | — | 0.26 Bn |
| 184 | MGNX | Macrogenics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -15.98 | 1.54 | 0.14 Bn |
| 185 | AVXL | Anavex Life Sciences Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -18.32 | — | 0.14 Bn |
| 186 | ANTX | AN2 Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -7.08 | — | 0.26 Bn |
| 187 | IVVD | Invivyd, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -3.04 | 4.55 | 0.10 Bn |
| 188 | CAMP | Camp4 Therapeutics Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -5.12 | 60.73 | 0.26 Bn |
| 189 | CYDY | CytoDyn Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.25 Bn | -7.41 | — | 0.25 Bn |
| 190 | KRRO | Korro Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | -2.87 | 99.68 | 0.12 Bn |
| 191 | CGEN | Compugen Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | 6.60 | 3.14 | 0.15 Bn |
| 192 | GLSI | Greenwich LifeSciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | -10.21 | — | 0.23 Bn |
| 193 | PYXS | Pyxis Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | -3.44 | 16.39 | 0.19 Bn |
| 194 | NMRA | Neumora Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -1.38 | — | 0.22 Bn |
| 195 | KROS | Keros Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -2.48 | 6.81 | -0.03 Bn |
| 196 | PEPG | PepGen Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -3.08 | — | 0.22 Bn |
| 197 | SRZN | Surrozen, Inc./DE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -3.57 | 18.90 | 0.22 Bn |
| 198 | ABOS | Acumen Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -2.06 | — | 0.22 Bn |
| 199 | PRQR | ProQR Therapeutics N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | -4.36 | 10.00 | 0.08 Bn |
| 200 | PLX | Protalix BioTherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | 10.07 | 2.64 | 0.17 Bn |
| 201 | FTH | Faeth Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | -1.07 | — | 0.21 Bn |
| 202 | CHRS | Coherus Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | -1.56 | 4.04 | 0.10 Bn |
| 203 | ARMP | Armata Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -3.27 | — | 0.18 Bn |
| 204 | ADCT | ADC Therapeutics SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -1.35 | 2.64 | -0.02 Bn |
| 205 | ADAG | Adagene Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -13.14 | 32.66 | 0.20 Bn |
| 206 | CUE | Cue Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -1.92 | 8.65 | 0.18 Bn |
| 207 | ORMP | Oramed Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | 1.14 | — | 0.19 Bn |
| 208 | NBP | NovaBridge Biosciences | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -2.47 | — | 0.19 Bn |
| 209 | IPHA | Innate Pharma SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -1.14 | 60.09 | 0.18 Bn |
| 210 | QNCX | Quince Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -2.41 | — | 0.18 Bn |
| 211 | MOLN | Molecular Partners Ag | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -2.51 | 214.11 | 0.18 Bn |
| 212 | XLO | Xilio Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | -5.54 | 2.71 | 0.04 Bn |
| 213 | OKUR | OnKure Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | -2.73 | — | -0.01 Bn |
| 214 | RANI | Rani Therapeutics Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | -4.87 | 32.81 | 0.16 Bn |
| 215 | MDWD | MediWound Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | -5.06 | 13.24 | 0.12 Bn |
| 216 | NGEN | Nervgen Pharma Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | -116.03 | — | 0.16 Bn |
| 217 | ENTX | Entera Bio Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | -10.45 | — | 0.14 Bn |
| 218 | MIST | Milestone Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | — | — | -0.02 Bn |
| 219 | IFRX | InflaRx N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | 0.00 | 1,813.85 | -0.04 Bn |
| 220 | MSLE | Satellos Bioscience Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | -2.74 | — | 0.14 Bn |
| 221 | SPRB | Spruce Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | -2.87 | — | 0.14 Bn |
| 222 | UNCY | Unicycive Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | -5.00 | — | 0.14 Bn |
| 223 | INDP | Indaptus Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -9.01 | — | 0.12 Bn |
| 224 | HURA | TuHURA Biosciences, Inc./NV | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -4.31 | — | 0.13 Bn |
| 225 | IBIO | iBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -3.99 | 1,316.36 | 0.13 Bn |
| 226 | CNTB | Connect Biopharma Holdings Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -1.88 | 43.87 | 0.13 Bn |
| 227 | NRXP | NRX Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -6.11 | 37.47 | 0.10 Bn |
| 228 | RFL | Rafael Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -4.74 | 129.12 | 0.13 Bn |
| 229 | BDTX | Black Diamond Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | -2.49 | — | 0.01 Bn |
| 230 | TLSA | Tiziana Life Sciences Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | -6.55 | — | 0.12 Bn |
| 231 | PMN | ProMIS Neurosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -2.66 | — | 0.06 Bn |
| 232 | GNLX | GENELUX Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -3.30 | — | 0.11 Bn |
| 233 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | — | — | -0.05 Bn |
| 234 | INO | Inovio Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -1.42 | — | 0.11 Bn |
| 235 | COYA | Coya Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -4.87 | 13.54 | 0.07 Bn |
| 236 | PLYX | Polaryx Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -10.11 | — | 0.09 Bn |
| 237 | CTOR | Citius Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -2.13 | 60.89 | 0.10 Bn |
| 238 | ONCY | Oncolytics Biotech Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -3.19 | — | 0.10 Bn |
| 239 | RLYB | Rallybio Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 2.07 | 145.65 | 0.09 Bn |
| 240 | ALDX | Aldeyra Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -3.94 | — | 0.09 Bn |
| 241 | KZIA | Kazia Therapeutics Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | — | — | 0.09 Bn |
| 242 | RVRC | Revium Rx. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -118.64 | — | 0.09 Bn |
| 243 | OTLK | Outlook Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -1.42 | — | 0.08 Bn |
| 244 | PYPD | PolyPid Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 2.75 | — | 0.08 Bn |
| 245 | ACRV | Acrivon Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -1.17 | — | 0.09 Bn |
| 246 | KLRS | Kalaris Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -1.76 | — | 0.08 Bn |
| 247 | FBIO | Fortress Biotech, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 10.06 | 1.22 | -0.11 Bn |
| 248 | MAIA | MAIA Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -3.03 | — | 0.05 Bn |
| 249 | ATHE | Alterity Therapeutics Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 0.00 | — | 0.08 Bn |
| 250 | GANX | Gain Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -4.17 | — | 0.08 Bn |
| 251 | TELO | Telomir Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -1.48 | — | 0.07 Bn |
| 252 | CRDF | Cardiff Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -1.75 | 123.88 | 0.07 Bn |
| 253 | SPRO | Spero Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | 11.91 | 1.47 | 0.02 Bn |
| 254 | DWTX | Dogwood Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -1.87 | — | 0.07 Bn |
| 255 | XBIT | XBiotech Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -1.61 | — | 0.07 Bn |
| 256 | HRTX | Heron Therapeutics, Inc. /De/ | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -7.12 | 0.42 | 0.02 Bn |
| 257 | ALGS | Aligos Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -0.84 | 15.80 | 0.03 Bn |
| 258 | SCYX | Scynexis Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -3.25 | 3.05 | -0.06 Bn |
| 259 | RNTX | Rein Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -1.13 | — | 0.06 Bn |
| 260 | IBO | Impact Biomedical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -2.92 | 1,571.11 | 0.05 Bn |
| 261 | MCRB | Seres Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.65 | 28.56 | 0.05 Bn |
| 262 | BDRX | Biodexa Pharmaceuticals Plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -6.38 | — | 0.04 Bn |
| 263 | IMMP | IMMUTEP Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.43 | 5.09 | 0.05 Bn |
| 264 | NMAD | Nomad Power Solutions, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -7.62 | — | 0.05 Bn |
| 265 | TIL | Instil Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -1.28 | — | 0.05 Bn |
| 266 | PTN | Palatin Technologies Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -7.83 | 3.81 | 0.05 Bn |
| 267 | ALP | Alpha Compute Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.02 | 0.19 | 0.05 Bn |
| 268 | HOWL | Werewolf Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -1.39 | 2.24 | 0.05 Bn |
| 269 | ATYR | aTYR PHARMA INC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.72 | 294.15 | -0.01 Bn |
| 270 | NXTC | NextCure, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.00 | — | 0.04 Bn |
| 271 | EDSA | Edesa Biotech, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -4.42 | — | 0.04 Bn |
| 272 | ELTX | Elicio Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.11 | — | 0.02 Bn |
| 273 | IMA | ImageneBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | — | — | -0.09 Bn |
| 274 | SER | Serina Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.49 | 323.62 | 0.02 Bn |
| 275 | ATNM | Actinium Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 3.46 | 1.11 | 0.04 Bn |
| 276 | MREO | Mereo BioPharma Group plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.00 | 77.17 | 0.04 Bn |
| 277 | LITS | Lite Strategy, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.66 | — | 0.03 Bn |
| 278 | FLNA | Filana Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.57 | — | 0.04 Bn |
| 279 | APLM | Apollomics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -3.72 | 4.79 | 0.03 Bn |
| 280 | CNTX | Context Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.77 | — | 0.04 Bn |
| 281 | KYNB | Kyntra Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.17 | 4.42 | 0.03 Bn |
| 282 | BETRF | BetterLife Pharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -21.82 | — | 0.04 Bn |
| 283 | BHST | Bioharvest Sciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -3.09 | 0.93 | 0.02 Bn |
| 284 | KAPA | Kairos Pharma, LTD. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -6.19 | 0.38 | 0.03 Bn |
| 285 | BRNS | Barinthus Biotherapeutics plc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -0.74 | — | 0.03 Bn |
| 286 | TAOX | TAO Synergies Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -1.40 | 40.00 | 0.03 Bn |
| 287 | ADIL | Adial Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -0.48 | — | 0.03 Bn |
| 288 | CLRB | Cellectar Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -1.26 | — | 0.03 Bn |
| 289 | YDESW | YD Bio Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | — | — | 0.03 Bn |
| 290 | IGC | IGC Pharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -12.26 | 93.50 | 0.03 Bn |
| 291 | RAPH | Raphael Pharmaceutical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -23.02 | — | 0.03 Bn |
| 292 | ABVC | Abvc Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -3.72 | — | 0.03 Bn |
| 293 | NNVC | Nanoviricides, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -2.91 | — | 0.02 Bn |
| 294 | RDPTF | Radiopharm Theranostics Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.28 | 97.58 | 0.02 Bn |
| 295 | VRXA | Veraxa Biotech AG - Post de-SPAC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.30 | 869.19 | 0.02 Bn |
| 296 | LTRN | Lantern Pharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.49 | — | 0.02 Bn |
| 297 | EVAX | Evaxion A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -2.45 | 2.83 | 0.01 Bn |
| 298 | GRDX | GridAI Technologies Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.13 | 261.63 | 0.02 Bn |
| 299 | JSPR | Jasper Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.10 | — | 0.02 Bn |
| 300 | DYAI | Dyadic International Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -2.60 | 4.87 | 0.01 Bn |